Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients Vandana Singh Mon, Apr 21, 2025, 8:05 AM 3 min read ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Enhertu + pertuzumab showed significant PFS improvement vs. THP in HER2+ metastatic breast cancer in DESTINY-Breast09 trial. Interim OS data favored Enhertu combo; safety profile aligned with ...